Dianthus Therapeutics Stock Performance
| DNTH Stock | 52.33 4.30 8.95% |
On a scale of 0 to 100, Dianthus Therapeutics holds a performance score of 15. The firm shows a Beta (market volatility) of -0.5, which means possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Dianthus Therapeutics are expected to decrease at a much lower rate. During the bear market, Dianthus Therapeutics is likely to outperform the market. Please check Dianthus Therapeutics' coefficient of variation, semi variance, period momentum indicator, as well as the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Dianthus Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Dianthus Therapeutics are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. Despite fairly conflicting basic indicators, Dianthus Therapeutics demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 9.85 | Five Day Return 19.04 | Year To Date Return 32.96 | Ten Year Return (77.29) | All Time Return (77.29) |
Last Split Factor 1:16 | Last Split Date 2023-09-12 |
1 | HighVista Strategies LLC Cuts Stake in Dianthus Therapeutics, Inc. DNTH | 12/12/2025 |
2 | Is Dianthus Therapeutics Inc. stock overvalued by current metrics - CPI Data AI Enhanced Trading Signals - | 12/19/2025 |
3 | Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 In Healthy Volunteers and Patients With Systemic Lupus Erythematosus | 12/23/2025 |
4 | Dianthus Therapeutics, Inc. DNTH Stake Lessened by Moody Aldrich Partners LLC - MarketBeat | 01/02/2026 |
5 | Dianthus CFO Sells 20,000 Shares for 903,600 After Massive Year-End Run | 01/07/2026 |
6 | Is Dianthus Therapeutics Inc. currently under institutional pressure - July 2025 Setups Growth Oriented Trading Recommendations - bollywoodhelpline.com | 01/14/2026 |
| Begin Period Cash Flow | 132.4 M | |
| Total Cashflows From Investing Activities | -286.8 M | |
| Free Cash Flow | -78.3 M |
Dianthus Therapeutics Relative Risk vs. Return Landscape
If you would invest 3,352 in Dianthus Therapeutics on October 25, 2025 and sell it today you would earn a total of 1,924 from holding Dianthus Therapeutics or generate 57.4% return on investment over 90 days. Dianthus Therapeutics is currently generating 0.8269% in daily expected returns and assumes 4.1244% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Dianthus, and 84% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Dianthus Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Dianthus Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Dianthus Therapeutics, and traders can use it to determine the average amount a Dianthus Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Based on monthly moving average Dianthus Therapeutics is performing at about 15% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Dianthus Therapeutics by adding it to a well-diversified portfolio.
Dianthus Therapeutics Fundamentals Growth
Dianthus Stock prices reflect investors' perceptions of the future prospects and financial health of Dianthus Therapeutics, and Dianthus Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Dianthus Stock performance.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.19 | ||||
| Operating Margin | (101.74) % | ||||
| Current Valuation | 1.66 B | ||||
| Shares Outstanding | 42.88 M | ||||
| Price To Book | 3.77 X | ||||
| Price To Sales | 669.05 X | ||||
| Revenue | 6.24 M | ||||
| Gross Profit | 3.08 M | ||||
| EBITDA | (101.45 M) | ||||
| Net Income | (84.97 M) | ||||
| Total Debt | 1.49 M | ||||
| Book Value Per Share | 12.75 X | ||||
| Cash Flow From Operations | (78.18 M) | ||||
| Earnings Per Share | (3.50) X | ||||
| Market Capitalization | 2.06 B | ||||
| Total Asset | 374.01 M | ||||
| Retained Earnings | (174.39 M) | ||||
| Working Capital | 262.45 M | ||||
About Dianthus Therapeutics Performance
By evaluating Dianthus Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Dianthus Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Dianthus Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Dianthus Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.26) | (0.27) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | (0.22) | (0.23) |
Things to note about Dianthus Therapeutics performance evaluation
Checking the ongoing alerts about Dianthus Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Dianthus Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Dianthus Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 6.24 M. Net Loss for the year was (84.97 M) with profit before overhead, payroll, taxes, and interest of 3.08 M. | |
| Dianthus Therapeutics generates negative cash flow from operations | |
| Dianthus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Is Dianthus Therapeutics Inc. currently under institutional pressure - July 2025 Setups Growth Oriented Trading Recommendations - bollywoodhelpline.com |
- Analyzing Dianthus Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Dianthus Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Dianthus Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Dianthus Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Dianthus Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Dianthus Therapeutics' stock. These opinions can provide insight into Dianthus Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Dianthus Stock analysis
When running Dianthus Therapeutics' price analysis, check to measure Dianthus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dianthus Therapeutics is operating at the current time. Most of Dianthus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dianthus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dianthus Therapeutics' price. Additionally, you may evaluate how the addition of Dianthus Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |